Clinical expertise

Professor Jenkins clinical focus is on interstitial lung disease and idiopathic pulmonary fibrosis in particular.


Professor Gisli Jenkins completed his medical training at University of Southampton before undertaking postgraduate training in respiratory medicine in London.

During this time he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from University College London before doing post-doctoral studies at University of California at San Francisco funded by an ARC Clinician Scientist Fellowship.

In 2005, he returned to the UK as a clinical senior lecturer at the University of Nottingham where he established the Academic Interstitial Lung Disease Unit. He was the pulmonary fibrosis work package lead for the MRC Nottingham Molecular Pathology Node, and the Nottingham Biomedical Research Centre.

He is currently the familial pulmonary fibrosis lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine and is the Post Hospitalisation (PHOSP)-COVID study Fibrosis Working Group lead and leads the UK Interstitial Lung Disease consortium.

He is an NIHR research professor and holds the Margaret Turner-Warwick chair of thoracic medicine at Imperial College London. He is the head of the Margaret Turner-Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute.


Prof Jenkins’ research focuses on interstitial lung diseases, and pulmonary fibrosis.

His team works to understand the biological basis for the development of pulmonary fibrosis and aims to translate this understanding in to improved outcomes for patients.

He is the Principal Investigator of a number of longitudinal observational studies including the PROFILE study, the INJUSTIS Study, the UKILD Post COVID ILD study as well as the DEMISTIFI multi-morbidity consortium.

He is the pulmonary fibrosis working group lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine, the PHOSP-COVID study and the HEAL COVID platform study.


Professor Jenkins has been the joint editor-in-chief of the official journal of the British Thoracic Society since 2015 and was chair of the British Thoracic Society Science and Research Committee from 2016-2018.

He is also the president of Action for Pulmonary Fibrosis and is the principle investigator of the Global REMAP-ILD Study.

He has also sat on a number of American Thoracic Society Committees and is co-chair of the International Colloquium of Lung and Airway Fibrosis.

He is a founding trustee of the patient charity Action for Pulmonary Fibrosis and is the clinical lead for the James Lind Alliance Priority Setting Partnership.


He was awarded the ERS Gold Medal in interstitial lung disease in 2020. In 2022 he became a fellow of the European Respiratory Society, and appointed president of Action for Pulmonary Fibrosis and has been awarded the BTS Meritorious Service Award for 2022.